Investing

Twelve Analyst Stocks Trading Under $10 With Huge Implied Upside

Halozyme Therapeutics Inc. (NASDAQ: HALO) was raised to Buy from Neutral and given a $16 price target by UBS this past Thursday. While the stock closed at $10.07 on Friday, the share price was $9.39 prior to the upgrade. We will leave it up to you to decide if the extra seven cents above 10 should have excluded it from the list. Our take: what is seven cents among friends?

MannKind Corp. (NASDAQ: MNKD) rose to $10.52 on Friday after a 7.5% gain, but the stock was at $9.78 when RBC Capital Markets started the speculative biotech player with an Outperform rating with a $16 price target. This is now the street-high target and implies more than 50% upside. We gave a full synopsis of this call and the FDA outlook on top of that ahead of next month’s key decision.

National Bank of Greece S.A. (NYSE: NBG) is going to have a solid Monday, regardless of what we say about. After all, Barron’s gave it a feature turnaround story this weekend. Still, we saw upgrades this last week. NBG was started with an Outperform rating at Credit Suisse, although the firm does note that it is skeptical about the bullish story for Greek banking stocks in general. The firm said that NBG is expected to cover its cost of capital in 2016 and 2017 under all three scenarios (bull, base, bear). Last week’s “analyst stocks under $10” included two positive research notes, one from Nomura, one from Deutsche Bank.

ALSO READ: 11 Ways to Avoid the Next Stock Market Crash

Navios Maritime Holdings Inc. (NYSE: NM) was started with a Buy rating on Wednesday by Canaccord Genuity. Its target was $14, implying upside of more than 40% from the $9.86 close on Friday. The stock did briefly rise above $10 on Thursday. Canaccord called it “head of the class.”

ON Semiconductor Corp. (NASDAQ: ONNN) was reiterated as Buy on Tuesday, but the price target was raised to $13 from $12 at Sterne Agee, after announcing a $400 million acquisition of Aptina Imaging in an accretive merger. Unfortunately, Morgan Stanley maintained its Underweight rating.

OraSure Technologies Inc. (NASDAQ: OSUR) was reiterated as Buy at Canaccord Genuity and the firm raised its price target to $11 from $10. Shares ended the week at $8.09, and the consensus price target is only $9.25. The firm said that more details will need to be seen, but it likes the AbbVie deal.

Orexigen Therapeutics Inc. (NASDAQ: OREX) was featured in more detail among our stocks that analysts say could double. Despite a three-month setback from the FDA on its obesity drug Contrave, several analysts see this $5.85 stock going much higher. On Thursday, Credit Suisse maintained its Outperform rating and $10 price target. Other target prices seen were $12 from Merrill Lynch and $16 from Leerink Swann.

Paragon Shipping Inc. (NASDAQ: PRGN) was given an analyst call saying that the stock could double. Canaccord Genuity initiated coverage on the small $114 million market cap stock with a Buy rating and gave it a $12 price target. Shares closed at $5.55 on Friday, and the consensus price target is just under $10. The firm sees a hidden value here.

ALSO READ: 10 Large Cap Stocks to Hold Forever

Sprint Corp. (NYSE: S) was raised to Outperform from Neutral by Macquarie this past Tuesday. The firm thinks that a Sprint merger is likely, and it opined that Sprint could be worth as much as $13 in the right scenario. We would also point out that Merrill Lynch said on Monday that it does not like Sprint, with or without T-Mobile. Sprint closed Friday at $8.73.

Last week’s analyst stocks to buy under $10 for huge implied upside included companies such as Abraxas Petroleum, Advantage Oil & Gas, Bio-Path, Halcon Resources, Hercules Offshore, ImmunoCellular Therapeutics, JAKKS Pacific, Kofax, Magnum Hunter Resources, National Bank of Greece, Rubicon Technology and SUPERVALU.

Sponsored: Find a Qualified Financial Advisor

Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.